Method for predicting platinum chemosensitivity of ovarian cancer patient by combining serum glycosylation modification with CA125

Abstract

Glycosylation modification in serum of an ovarian cancer patient before treatment is detected, and the sensitivity of the ovarian cancer patient to platinum chemotherapeutic drugs is subjected to prognosis evaluation by combining alpha 2, 3 sialic acid N-sugar chains with CA125. A detection object of the kit is serum of an ovarian cancer patient before treatment; the method comprises the followingsteps: detecting serum glycosylation modification by using an analytical instrument, calculating the relative expression quantity of alpha 2, 3 sialic acid type N-sugar chains, and performing binarylogistic regression analysis in combination with the content of CA125 in serum of a patient by using SPSS software to obtain a prediction probability; taking 0.24 as a critical value, if the prediction probability is greater than 0.24, determining that the patient is a drug-resistant patient, and if the prediction probability is less than 0.24, determining that the patient is a sensitive patient.The method has the advantages that the chemotherapy effect of the medicine on the patient is predicted by utilizing the proper marker, a treatment scheme more suitable for the patient is selected, andthe survival rate of the ovarian cancer patient is further improved.

Description

technical field [0001] The present invention relates to the field of biotechnology. Background technique [0002] Ovarian cancer is the most lethal gynecological tumor. At present, serum CA125 and ultrasound are the most common detection methods; most patients are treated with tumor annihilation combined with chemotherapy. Currently, the first-line chemotherapeutic drug for ovarian cancer is platinum combined with paclitaxel. Although most patients are sensitive to platinum-based drugs during the initial chemotherapy, most patients will relapse with drug resistance, so the five-year survival rate of ovarian cancer patients is not high, and the prognosis is poor. Clinically, 6 months is usually used as the time point to distinguish patients' sensitivity to drugs. If the time from the end of platinum-based chemotherapy to relapse is less than 6 months, it is defined as a drug-resistant patient; if it is longer than 6 months, it is defined as a sensitive patient. If appropr...

AI Technical Summary

Problems solved by technology

[0004] Some researchers have tried to find markers to distinguish the sensitivity of ovarian cancer patients to chemotherapy, so as to evaluate the treatment plan of patients before treatment, but so far, no suitable markers have been found, and the use of glycosylation modification in pre-treatment No studies have been reported to differentiate chemotherapy sensitivity in patients with ovarian cancer

Images